Skip to main content
SENORES PHARMACEUTICALS LIMITED logo

SENORES PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · SENORES ISIN · INE0RB801010 LEI · 984500FQ4CDFAFBBD763 BSE.NS Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2025-12-15 Capital/Financing Update
Country IN India
Listing BSE.NS SENORES

About SENORES PHARMACEUTICALS LIMITED

https://senorespharma.com/

Senores Pharmaceuticals Limited is an R&D-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex generic formulations. The company focuses on niche therapeutic segments and specialty products, including oral solids, liquids, and topicals, with a significant emphasis on complex injectables and ophthalmic solutions. Senores leverages its advanced research capabilities to address unmet medical needs in highly regulated global markets, particularly the United States. Its business model integrates end-to-end capabilities from product identification and formulation development to regulatory filing and global distribution. The company is committed to delivering high-quality, affordable healthcare solutions through strategic partnerships and a robust pipeline of value-added medicines designed to improve patient outcomes in specialized clinical areas.

Recent filings

Filing Released Lang Actions
General Updates
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the company's entry into a Share Purchase Agreement to acquire 100% share capital of another company, Apnar Pharma Private Limited. The document includes detailed disclosure as required by SEBI regulations about the acquisition, such as the target company details, consideration, percentage acquired, and timeline for completion. This type of filing is a regulatory announcement about a material event affecting the company, specifically an acquisition transaction. It is not a full merger proxy statement (MA), nor a detailed management report or financial report. It is an update on a capital transaction and acquisition. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6660 characters) and content confirm it is a substantive announcement, not just a brief notice or report publication announcement.
2025-12-15 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a media release announcing the approval and launch of a pharmaceutical product by Senores Pharmaceuticals. It is addressed to stock exchanges and references compliance with SEBI Listing Obligations and Disclosure Requirements. The content focuses on the product launch, company background, and forward-looking statements. There are no financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The document is a public announcement intended for investors and the market about a business development event. Therefore, it fits best under the category of Capital/Financing Update (CAP), which includes updates on company activities that impact growth and market position, such as product launches and strategic initiatives.
2025-12-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing them about the schedule of analyst and institutional investor meetings (Non-Deal Roadshow). It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The content is about announcing the schedule of investor meetings and does not contain any financial data, report, or detailed presentation. The document length is short (2114 characters) and it is an announcement rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-12-05 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a media release announcing that Senores Pharmaceuticals has received Philippine FDA approval for 10 products. It is addressed to stock exchanges and mentions that the media release is being uploaded on the company's website. The content focuses on regulatory approval news and business expansion strategy, without any financial statements, earnings data, or detailed financial analysis. The document is not a financial report, earnings release, or management discussion. It is a public announcement of a corporate development. Therefore, it fits best under the category of a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call for Q2 and H1 FY26 of Senores Pharmaceuticals Limited. It includes detailed management commentary on financial performance, segment-wise revenue, EBITDA, PAT, cash flow, and future outlook. The text explicitly mentions it is a transcript of the earnings call held on November 6, 2025, and includes Q&A session initiation. The document is about 15,000 characters long, containing the full transcript rather than a brief announcement or summary. Therefore, it fits the definition of a Call Transcript (CT) rather than an Earnings Release (ER) or Interim Report (IR).
2025-11-13 English
Copy of Newspaper Publication
Earnings Release Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE Limited and National Stock Exchange of India Limited) regarding the publication of un-audited financial results for the quarter and half year ended September 30, 2025. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulations 30 and 47, which pertain to disclosure and publication of financial results. The document includes newspaper publication extracts of these un-audited standalone and consolidated financial results. The content is focused on announcing the publication of these financial results rather than containing the full detailed financial statements or analysis itself. The document length is 15,000 characters, but the main body is a notification letter with attached newspaper extracts, which are summaries or excerpts of the financial results. This fits the profile of an Earnings Release (ER) because it announces quarterly/periodical financial results with key highlights, not a full Annual or Interim Report. It is not a full Interim/Quarterly Report (IR) because it does not contain comprehensive financial statements or substantive financial data and analysis, only extracts. It is not a Report Publication Announcement (RPA) because it includes the extracts themselves, not just a notice of report availability. Therefore, the best classification is Earnings Release (ER). H1 2025
2025-11-07 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.